🇺🇸 FDA
Patent

US 10570140

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

granted A61KA61K31/7064A61P

Quick answer

US patent 10570140 (Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)) held by Prelude Therapeutics, Incorporated expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Prelude Therapeutics, Incorporated
Grant date
Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K31/7064, A61P, A61P35/02